Objective This European, multicentric, retrospective study aimed to collect data on secukinumab effectiveness in a real-world setting. Research design and methods: All psoriatic patients starting secukinumab between January 2016 and February 2017 in 11 European centers were followed until February 2018 and retrospectively evaluated. Main outcome measures: Secukinumab effectiveness was assessed by relative improvement from baseline of the Psoriasis Area Severity Index (PASI) and absolute PASI score modifications throughout 52 weeks of therapy. Additionally measures assessing effectiveness were used, including improvements of body surface area (BSA) and Dermatology Life Quality Index (DLQI). Results Out the 330 patients with potentially 52-week treatment duration, naïve to biologics patients showed greater probability to achieved PASI score of ≤1, ≤2, ≤3, and ≤5 at week 12, compared to bio-experienced patients (45.86% vs. 27.17%, 62.42% vs. 42.42%, 73.89% vs. 57.80%, and 84.08% vs. 74.57%, respectively). The greater effectiveness of secukinumab treatment in bio-naïve patients was confirmed at week 24 and 52. Conclusions In this real-world experience, secukinumab was proven effective in treating psoriasis patients throughout a 52-weeks observation period, with higher response in bio-naïve patients. This study may contribute to defining the clinical profile of secukinumab best-responders.

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: Results from a European, multicentric, retrospective, real-world study / Chiricozzi, Andrea; Balato, Anna; Conrad, Curdin; Conti, Andrea; Dapavo, Paolo; Ferreira, Paulo; Gaiani, Francesca Maria; Leite, Luiz; Malagoli, Piergiorgio; Mendes-Bastos, Pedro; Megna, Matteo; Messina, Francesco; Nidegger, Alessia; Odorici, Giulia; Panduri, Salvatore; Piaserico, Stefano; Piscitelli, Leonardo; Prignano, Francesca; Ribero, Simone; Valerio, Joana; Torres, T. - In: THE JOURNAL OF DERMATOLOGICAL TREATMENT. - ISSN 0954-6634. - (2020), pp. 1-24-24. [10.1080/09546634.2019.1671577]

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: Results from a European, multicentric, retrospective, real-world study

Balato, Anna;Megna, Matteo;
2020

Abstract

Objective This European, multicentric, retrospective study aimed to collect data on secukinumab effectiveness in a real-world setting. Research design and methods: All psoriatic patients starting secukinumab between January 2016 and February 2017 in 11 European centers were followed until February 2018 and retrospectively evaluated. Main outcome measures: Secukinumab effectiveness was assessed by relative improvement from baseline of the Psoriasis Area Severity Index (PASI) and absolute PASI score modifications throughout 52 weeks of therapy. Additionally measures assessing effectiveness were used, including improvements of body surface area (BSA) and Dermatology Life Quality Index (DLQI). Results Out the 330 patients with potentially 52-week treatment duration, naïve to biologics patients showed greater probability to achieved PASI score of ≤1, ≤2, ≤3, and ≤5 at week 12, compared to bio-experienced patients (45.86% vs. 27.17%, 62.42% vs. 42.42%, 73.89% vs. 57.80%, and 84.08% vs. 74.57%, respectively). The greater effectiveness of secukinumab treatment in bio-naïve patients was confirmed at week 24 and 52. Conclusions In this real-world experience, secukinumab was proven effective in treating psoriasis patients throughout a 52-weeks observation period, with higher response in bio-naïve patients. This study may contribute to defining the clinical profile of secukinumab best-responders.
2020
Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: Results from a European, multicentric, retrospective, real-world study / Chiricozzi, Andrea; Balato, Anna; Conrad, Curdin; Conti, Andrea; Dapavo, Paolo; Ferreira, Paulo; Gaiani, Francesca Maria; Leite, Luiz; Malagoli, Piergiorgio; Mendes-Bastos, Pedro; Megna, Matteo; Messina, Francesco; Nidegger, Alessia; Odorici, Giulia; Panduri, Salvatore; Piaserico, Stefano; Piscitelli, Leonardo; Prignano, Francesca; Ribero, Simone; Valerio, Joana; Torres, T. - In: THE JOURNAL OF DERMATOLOGICAL TREATMENT. - ISSN 0954-6634. - (2020), pp. 1-24-24. [10.1080/09546634.2019.1671577]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/761100
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 24
social impact